BioSpace News Archive

Aimmune Therapeutics, today announced the launch of PACT-CP, a Patient-Centric Chronic Pancreatitis Registry study to better understand the unmet needs and therapeutic burden on patients with EPI due to chronic pancreatitis (CP).

Besides causing much illness and death, the SARS-CoV-2 virus with its COVID-19 disease has been a major ally of those seeking to impose a radical collectivist ideology and to expand their control of our lives at any cost, writes Marilyn Singleton, M.D., J.D., in the summer issue of the Journal of American Physicians and Surgeons.

DiFusion Technologies, maker of the ZFUZE™ suite of surgical polymers, today announced the addition of Todd Potokar to its Board of Directors.

EvoEndo® Inc., (“EvoEndo” or “the Company”) a preclinical medical device company developing systems for unsedated Transnasal Endoscopy (TNE), announced it has secured $10.1M in equity financing.

Dr. Dennis Gross Skincare announces a donation to Memorial Sloan Kettering Cancer Center, pledging a $100,000 contribution to fund melanoma fellowships with the goal to develop more effective strategies for detecting, preventing, controlling and, ultimately, curing skin cancer.

The American Academy of Pediatrics debuts the 8th Edition of its internationally recognized Neonatal Resuscitation Program® in June.

Kaiser Permanente, the nation’s largest integrated, nonprofit health care provider, is joining the White House for its National Month of Action sprint to vaccinate 70% of adults in the U.S. against COVID-19 with at least one shot by July 4.

The conference will be held virtually on July 13 and 14. Greg McKee, Chairman and CEO; Jim Gilligan, President and Chief Science Officer; and Luke Hayes, CFO, will provide an overview of Tryp’s business and its pipeline followed by a brief analyst-led fireside chat.

Francis Medical, Inc., today announced positive results from the company’s VAPOR 1 clinical study evaluating the safety and efficacy of the company’s minimally invasive water vapor ablation therapy for treating prostate cance

Cybrexa Therapeutics, today announced that NAR Cancer, a fully open access journal publishing original research and survey and summary articles at the intersection of the nucleic acids research and cancer fields, has published a peer-reviewed study of CBX-12, Cybrexa’s lead candidate.